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16.7 NUTRITION
1. GENERAL CONSIDERATIONS
jj Malnutrition is the consequence of an imbalance between energy intake and energy needs. 
CF patients are at risk for undernutrition because of disproportionately high energy needs 
compared to the energy intake. 
jj Undernutrition influences CF patient outcomes adversely: 
js The relationship between nutrition and respiratory function is well established as FEV1 
decreases with lower body mass index (BMI) (Figure 1). 
js Undernutrition and deficiency of nutrients, such as essential fatty acids or fat-soluble 
vitamins, have also a deleterious effect on muscle function, immune defenses and may 
also be related to CF-related liver disease and osteoporosis (Figure 2).
js Undernutrition is an independent risk factor for morbidity and mortality. 
Of note, emphasis on optimal nutrition at all ages and the introduction of high-calorie, 
high-fat diet as the standard of CF care are considered turning points in the history of 
CF leading to improved survival.
jj
jj
Table 1 summarizes predisposing factors for undernutrition in adult CF patients.
The prevalence of undernutrition in adult CF patients varies from 8-38% depending on the 
used definition, the country, the patient’s age and the severity of CF. 
sj In Switzerland, according to the 2016 ECFS Registry report, the median BMI is 21.5 kg m2 
for adult male patients and 20.3 kg/m2 for adult female patients, values which are slight-
ly lower than the BMI recommended by the ESPEN-ESPGHAN-ECFS guidelines 
which is 23 kg/m2 for male patients and 22 kg/m2 for female patients.
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Figure 1: Percentage predicted FEV1 and BMI in adult CF patients 20 to 40 years 
old (reprinted with permission from the Cystic Fibrosis Foundation, 2017 Patient 
Registry Annual Data Report1)
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Figure 2: Consequences of malnutrition in CF (adapted from2)
jj During the transition period from pediatric to adult care, the pediatric CF team should 
inform the adult CF team about the evolution of the weight-for-height growth and also the 
measures taken to optimize growth and nutritional status during childhood.  
2. NUTRITIONAL ASSESSMENT
jj Nutritional assessment should be performed in close collaboration with dieticians.
jj The main components of nutritional assessment include the clinical history, the cur-
rent body weight and weight changes, the physical examination, body composi-
tion and laboratory data (Table 2).  
jj The ESPEN guidelines recommend:
js Measurement of height and weight in adolescents, and weight in adults at least every 3 
months to assess BMI. 
6.7 Nutrition 20190428.indd   2 08/05/19   10:40 AM
36.7 NUTRITION
Table 1: Risk factors for undernutrition in adult CF patients (adapted from3)
Organs Causes
Respiratory tract Pulmonary exacerbations
Severe lung disease
Chronic rhinosinusitis
Digestive system Pancreatic insufficiency
Gastroesophageal reflux disease 
Recurrent pancreatitis
Small bowel bacterial overgrowth
Celiac disease
Constipation
Distal intestinal obstruction syndrome (DIOS) 
Diarrhea
Inflammatory bowel diseases
CF liver disease
Motility disorders
Eosinophilic gastrointestinal disease
Endocrine system CF-related glucose intolerance/diabetes
Psychosocial Body image disorders
Anxiety/depression
Stress
Low income
Time spent for treatment
Miscellaneous Adverse drug effects
2.1 Body composition 
jj In practice, the study of body composition is based on 2 compartments: 
a) the fat mass (FM) and
b) the lean mass (LM) which includes water, protein mass and bone mass.
jj Body composition is of major interest in CF since it gives information on the pro-
portion of FM and LM and on the level of hydration of the patient. At the beginning 
of a malnutrition state, it is common to observe a reduction of the FM with a preserved LM.
jj Body composition can be assessed by a number of different techniques, however not all 
have been validated in CF.
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– body composition (see paragraph 2.1) by different methods such as dual-energy
X-ray absorptiometry (DEXA) or bioelectrical impedance (BIA) and
– assessment of bone mineral density by DEXA (see Chapter “Bone disease”).
jj Patients at risk for malnutrition (Figure 3 at the end of this chapter) should be evaluated 
more frequently and their evaluation should be multidisciplinary (dietician, gastroenterolo-
gist, endocrinologist and psychologist).
sj Routine measurement of 
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Table 2: Components of the nutritional assessment (adapted from4,5) 
Parameters Frequency
Clinical history  – History of intestinal resection
 – History of recurrent pancreatitis
 – CF-related diabetes
 – CF liver disease
 – Nephrolithiasis
 – Bone disease
At first visit and 
when needed
Current history  – Gastrointestinal transit
 – Pancreatic sufficiency status
 – Food intake
 – Psycho-social problems that may influence
nutrition
At each clinic visit 
(at least every 3 
months)
Treatment  – Compliance
 – Pancreatic enzyme replacement therapy (PERT)
 – Vitamin substitution and calcium substitution, oral
nutritional supplements and/or enteral nutrition,
insulin etc
At each clinic visit 
(at least every 3 
months)
Clinical 
assessment
– Emotional status, asthenia, strength, dyspnea
– Appetite, satiety, gastrointestinal symptoms
– Physical activity
– Weight, height, BMI, weight loss or gain, muscle
wasting
At each clinic visit 
(at least every 3 
months)
Dietary review  – Food intake (24h recall, 3-5-day diet record*) At least every 6 
months
Body 
composition
 – Triceps skinfold thickness and mid-arm muscle
circumference
 – BIA
 – DXA (if available and clinically indicated)
At least annually
Standard 
 biological 
assessment
 – CBC, PT, electrolytes, renal and liver function,
glucose level, C-reactive protein, albumin,
prealbumin
 – Lipid status for patients >40 years old or CF-
related diabetes or with a family history of
hyperlipidemia
At least annually
Specific biologi-
cal assessment
 – Liposoluble vitamins: A, D, E and INR as an indi-
cator of vitamin K status
 – Minerals : calcium, magnesium, phosphate
At least annually
BIA: bioelectrical impedance, BMI: body mass index, DXA: dual-energy X-ray absorptiometry 
*For CF patients at risk for malnutrition, the 3-5-day diet record may be necessary to assess energy and nutrient intake 
more accurately. 
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js Anthropometry (tricipital skinfold and arm circumference): hand grip strength, trici-
pital skinfold thickness measurement using Holtain caliper and the arm muscle cir-
cumference are easy to perform. They can easily provide proof of subcutaneous fat 
loss or muscle wasting. Measures are compared to Frisancho’s standard deviation 
percentiles.
js Bioelectrical impedance (BIA): BIA is a simple and noninvasive method that does not 
expose to radiation. It has been validated for a BMI between 18 and 34 kg/m2 and it is 
also validated in the CF population. It is based on the difference between the electrical 
resistance of fat (high resistance) and lean (low resistance) components of the body. 
 – Skin electrodes are placed on the patient and the resistance of electric power that
flows through the tissues is converted into total body volume of water, fat mass and
lean mass using standardized equations.
 – The test takes about 15 min to perform and requires minimal operator training.
 – It allows to evaluate changes of body composition over time. However, rapid hydroe-
lectric variations disturb the measurement.
js DXA: initially used for bone density assessment, it has recently become the reference 
tool for body composition measurement. 
 – It is considered to be accurate and precise. It not only makes possible to determine
the total FM, but also the segmental FM.
 – Body composition DXA does not depend on weight or size, it exposes to low radiation 
and does not require special preparation.
 – However, it is not transportable, not applicable for extreme weight and height (height in 
the machine> 1.82 cm,> 135 kg), it is expensive and requires a radiology technician.
3. NUTRITIONAL INTERVENTION
3.1 Hydration
jj Body composition assessment shows that, frequently, CF patients are not well hydrated. 
Signs of dehydration include thicker sputum and constipation.
jj The recommended daily fluid intake is ≥ 35-45 ml/kg (2.5-3.0 L/day for an individual of 70 
kg) (Table 3). 
jj Hydratation must be adapted in specific situations such as exercise, hot weather condi-
tions, increased fluid losses (e.g. when there is fever, vomiting or diarrhea). 
3.2 Macronutrients
jj Table 3 summarizes the recommended energy, protein, fat and carbohydrate intake in CF. 
3.3 Micronutrients, minerals and trace elements other than vitamins
3.3.1 Sodium
jj Daily salt intake for adult CF patients should be about 4’000 to 6’000 mg NaCl which is 2-3 
times more than for a non-CF adult.
jj Supplementation should be considered in high risk patients (fever, exercise, hot weather) 
or when the intake of salt is reduced (illness with poor appetite).  The loss of sodium can 
be increased by 10 times during exercise in hot climates. 
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Table 3: Summary of recommended daily intake in CF
Recommended daily intake Comments
Energy-calories* 110-200% compared to a healthy
population of the same age (namely
30 kcal/kg/day)
Goal: normal BMI
Proteins 1.2-1.5 g/kg/day Depending on the degree of 
malabsorption, pancreatic 
enzyme supplementation and 
chronic inflammation, the target 
for protein intake is ≥ 20% 
compared to a healthy population 
of the same-age.
Fat* 35-40% of total energy intake
Carbohydrates 40-45% of total energy intake In diabetic patients, reduction 
of carbohydrates intake is not 
recommended (rather the insulin 
dose should be adapted).
Fluids ≥ 35-45 ml/kg To be increased in case of 
excessive loss (fever, exercise, 
hot weather conditions, vomiting, 
diarrhea)
Sodium 4’000-6’000mg of NaCl 
(1 teaspoon of salt ≅ 5’000 mg of 
NaCl ≅ 2’000 mg of Na ≅ 85 mmol 
of Na) 
Maximum intake 8’000 to 12’000 mg
Increase salty food intake if 
more salt is needed or use NaCl 
slow release pills or rehydration 
solution (Table 4).
Calcium 950-1000 mg ≥ 3 dairy portions/day (Table 5)
*The introduction of a high-calorie, high-fat diet as the standard of care in CF is considered one of the major turning
points in the history of CF leading to improved survival
jj In adult CF patients, the ESPEN guidelines recommend to compensate for sodium loss by 
increasing salty food intake. Rehydration solutions or supplemental NaCl (Table 4) can 
also be used in situations associated with increased sodium loss.
jj The ESPEN guidelines propose to determine NaCl needs for supplementation by calcu-
lating the fractional excretion of sodium (FENa) with a target between 0.5% and 1.5% or sim-
ply by calculating the urinary Na:creatinine ratio (17-52mmol/mmol) which correlates to FENa. 
FENa has been used for children and is obviously not very useful on a daily basis. However, in 
case of severe salt depletion in adults, FENa may be used to better adjust salt replacement.
3.3.2 Calcium
jj Lack of calcium may be due to insufficient calcium intake, low absorption because of vita-
min D deficiency and/or fecal losses. 
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jj Serum calcium is not a good predictor of calcium deficiency as 99% of calcium stock is 
located in the bony skeleton. Therefore, evaluation of calcium intake is recommended 
annually. 
jj The European Food Safety Authority recommends a calcium intake of 950-1000 mg cal-
cium/day and the Swiss Society of Nutrition the consumption of at least 3 dairy portions/
day (see also Chapter “Bone disease”). 
jj Table 5 gives some examples of the calcium content of different dairy portions.
3.3.3 Magnesium
jj Hypomagnesemia may develop due to:
js insufficient intake
js poor intestinal absorption because of exocrine pancreatic insufficiency and/or use of PPIs
js hyperglycemia with excessive urinary magnesium excretion and 
js some medications which increase renal loss of magnesium such as thiazide diu-
retics,  bisphosphonates, calcineurin inhibitors and aminoglycosides. Cases of te-
tany associated to hypomagnesemia have been described following high doses of 
aminoglycosides.
Table 4: Examples of salt supplementation and rehydratation solutions 
 available in Switzerland
Normolytoral® 
1 bag powder
1 bag in 200ml of water, 
1-20x/day
Elotrans®  powder
1 bag powder
Sodium chloride (350 mg) 
Citrate of sodium dihydrate (590 mg) 
Potassium chloride (300 mg) 
Glucose (4 g)*
Sodium chloride (700 mg)
Citrate of sodium dihydrate (590 mg) 
Potassium chloride (300 mg) 
Glucose (4 g)*
1 bag in 200ml of water, 
1-10x/day
NaCl caps Sodium chloride (500 mg) 1-4caps/day
1 teaspoon of salt ≅ 5’000 mg of NaCl ≅ 2’000 mg of Na ≅ 85 mmol of Na
*Intestinal sodium transport is stimulated by the presence of glucose (sodium-glucose co-transport)
Table 5: Calcium content of different dairy portions (based on the Swiss 
Society of Nutrition)*
Type of food Volume/weight Calcium (mg)
Whole/drink milk 200 ml 240
Yoghurt 180 g 252
Hard cheese 30 g 273
Soft cheese 60 g 264
* See also http://www.sge-ssn.ch/media/Etage_lait_produits_laitiers.pdf
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jj Blood levels are not representative of the body storage of magnesium, because the major 
amount of magnesium is in the muscles and the bone.
jj Low magnesium may contribute to muscle cramps and to delayed bowel transit time.
3.3.4 Selenium
jj Selenium is part of the active site of glutathione peroxidase which has important an-
tioxidant activity. Lack of selenium can affect muscle function and result to cardiopathy. 
However, because of a narrow therapeutic range, supplementation in selenium is 
not recommended. 
jj Reference values for daily nutritional intake of selenium established by the DACH (Societies 
of Nutrition from Germany, Austria and Switzerland) for non-CF adult individuals is between 
60-70 µg.
jj Multivitamin preparations designed for CF may contain supplementation in selenium. For 
example, one pill of DEKA’s softgel contains 75 µg of selenium.  
3.3.5 Zinc
jj Zinc plays an important role in various enzymes. Zinc deficiency is associated with growth 
retardation, increased susceptibility to infections, delayed sexual maturation and eye 
problems.  
jj Its absorption depends on exocrine pancreatic function and the use of PERT. 
jj Plasma levels of zinc are of limited interest because of their large variability. 
jj The ESPEN guidelines recommend supplementation for patients at risk, particularly those 
with vitamine A deficiency and steatorhea (25 mg/day during 6 months). 
jj One pill DEKA’s softgel contains 10 mg zinc sulfate. Other preparations available in 
Switzerland are listed in Table 6.
3.3.6 Iron
jj Iron not only plays an essential role in oxygen binding but it is also involved in many en-
zymatic activities and is necessary for cognitive function. In CF, it is also related to the 
severity of lung disease. 
jj Iron deficiency is very common. Multiple causes of iron deficiency may exist in CF: ma-
labsorption, inflammation, chronic infection, insufficient intake (e.g. calcium inhibits iron 
absorption) and blood losses. If not compensated, iron deficiency will progress to hypo-
chromic microcytic anemia. 
Table 6: Examples of zinc supplementation available in Switzerland
Name/Type/Dosage Active ingredient Daily posology
ZINK BIOMED® 20 mg cpr pell Zinc gluconate 1-2 coated tablets
ZINC BURGERSTEIN® cpr 30 mg Zinc gluconate 1 coated tablet
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jj
jj
jj
jj
jj
As ferritin is an acute phase protein, its blood levels are not easy to interpret in CF (it may 
be normal even when the iron stores are depleted).  Only serum transferrin receptors are 
not influenced by inflammation and may be a more appropriate marker to detect iron defi-
ciency. However, this test is not easily available.
If anemia occurs, then measurements of total iron level, ferritin, or transferrin saturation are 
proposed to characterize the type of anemia (Table 7). 
The ESPEN guidelines suggest to measure iron levels annually and, if they are low, to 
complete with another analysis to determine the cause of anemia (iron deficiency vs chro-
nic inflammation). Supplementation is recommended if the deficiency persists despite the 
treatment of the inflammatory state (Table 8). However, nowadays, free iron level is consi-
dered obsolete as it does not represent total iron storage.
Iron deficiency without anemia may also be symptomatic (fatigue, hair loss) and should 
be treated.  Therefore, in the presence of a low ferritin (< 30 µg/ml) and low MCV despite 
normal hemoglobin (Hb), some centers recommend to supplement with iron preparations, 
especially liquid formulas as they are better tolerated. The effect of this supplementation 
should be evaluated after 3 months and the treatment readapted accordingly. 
In CF patients not tolerating oral forms of iron, intravenous ferric carboxymaltose (Table 8) 
may be considered but with caution:
sj Pseudomonas aeruginosa can acquire iron from the host and its survival depends 
on iron accessibility from the environment. Six per cent of transcribed genes of P. aeru-
ginosa are iron-responsive. Iron also plays a role in biofilm formation. 
sj For different reasons including epithelial leakage, iron accumulates in CF airways and is 
present in micromolar concentrations.
Table 7: Differential diagnosis between different types of anemia (adapted from 6)
Test Iron 
deficiency
Iron 
deficiency 
anemia 
Anemia of 
chronic 
inflammation
Both forms 
of anemia
Hemoglobin
(N: F >120, M>130 g/l)
Normal Low Low Low
MCV
(N: 80-95 fl)
Normal <80 Low-normal Low
Serum iron*
(N: 10-30 µmol/l)
Low Low Low Low
Serum ferritin [µg/l]
(N: F 20-200, M 40-300 µg/l)
Below normal Above normal Varies 
Transferrin saturation
(>16years of age N <45%)
≥16 <16 Low-normal Below normal
sTFR** High High Low-normal Variable
MCV: mean corpuscular volume; sTFR: soluble transferrin receptor
*Considered obsolete (see text).
**Normal values depend on the assay used
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js Respiratory exacerbations have been reported following supplementation with intrave-
nous iron however a causal relationship has not been proven. Although a direct compa-
rison between IV and oral iron is not available in this regard, it has been hypothesized 
that a differential effect of IV vs oral iron on hepcidin may play a role. Hepcidin is a 
hormone that regulates iron-homeostasis and is produced by the liver. After oral admi-
nistration of iron, hepcidin levels increase to reduce intestinal absorption and to keep 
the iron in the reticulo-endothelial system away from pathogens. In contrast, following 
administration of IV iron, this mechanism does not occur.
jj
jj
Because of the potential negative impact of the intravenous form of iron and in the ab-
sence of clinical studies and recommendations, we prefer to administer a weekly, 
low dose of ferric carboxymaltose such as 200-300 mg/perfusion until the total dose is 
reached, instead of a single high dose. In addition, this medication should be avoided 
during exacerbations. 
The calculated dose of ferric carboxymaltose is based on the Ganzoni’s formula:
Total iron deficit [mg] = weight [kg] × (target Hb – actual Hb) [g/dl] × 2,4 + iron 
stores [mg] (for weight > 35 kg, iron stores = 500 mg)
3.4 Fat-soluble vitamins
jj Deficiency of water-soluble vitamins (folic acid, vitamin B12, vitamin C) is rare in CF. Patients 
with extensive resection of terminal ileum are at high risk for vitamin B12 deficiency.
jj Deficiency of fat-soluble vitamins is frequent in CF patients, although it is very uncommon 
for adult CF patients to have obvious clinical signs in this regard. It results from pancreatic 
insufficiency, malabsorption and/or hepato-biliary disease. Occasionally, pancreatic suffi-
cient patients may also suffer from fat-soluble vitamins deficiency.
jj Measurement of fat-soluble vitamins A, D, E plasma levels and prothrombin time, INR 
(as an indirect marker of vitamin K status – see also paragraph 3.4.4 Vitamin K) is 
Table 8: Examples of iron monopreparations available in Switzerland*
Name/Type/Dosage Active ingredient Daily dose
FERRUM HAUSMANN®
caps. 100 mg
Ferrous fumarate [Fe(II)] 100-300 mg
MALTOFER®
cpr 100 mg
liquid form 50 mg/20 drops
Ferric hydroxide-
polymaltose [Fe(III)
100-300 mg for iron deficiency
anemia
50-100 mg for iron deficiency
without anemia
TARDYFERON®
cpr 80 mg
Ferrous sulfate [Fe(II)] 80-160 mg
FERINJECT®
50 mg/ml for IV administration
Ferric carboxymaltose 
[Fe(III)]
Determined by Ganzoni’s 
formula 
*The IV forms of iron may occasionally result in immediate hypersensitivity reactions and for this reason administration 
is recommended in a healthcare setting followed by patient surveillance for at least 30 min after administration.
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jj
recommended annualy. Supplementation of vitamins A, D, E and K should be initiated in 
case of deficiency. 
sj The recommended daily dietary allowances for fat-soluble vitamins in CF are summa-
rized in Table 9.
sj Treatment aims to correct suboptimal levels and to reach optimal biochemical values of 
these vitamins (according to the normal values of the laboratory). 
sj Vitamin blood levels should be checked 3-6 months after dose adaptation.
To improve vitamin absorption, fat-soluble vitamins should be taken concomitant-
ly with high fat food and pancreatic enzyme supplements (Tables 5, 6 and 7 and 
Chapter “Exocrine pancreatic insufficiency”).
3.4.1 Vitamin A
jj
jj
jj
Because of decreased levels of retinol binding protein, patients suffering from CF-liver 
disease may be at risk of hypervitaminosis A. In these cases, in addition to serum retinol it 
is recommended to measure also serum retinyl binding protein and retinyl esters.
Beta-carotene is probably safer than retinol supplementation as it is a provitamin A.
During pregnancy, hypo- or hypervitaminosis A may be harmful for the fetus and should 
be closely monitored. Supplementation should not exceed 10’000 IU/day (see Chapter 
“Safety of medication use during pregnancy and breastfeeding” ).
3.4.2 Vitamin D
jj
jj
Vitamin D deficiency is frequent in CF despite oral supplementation and contributes to a 
lower bone density.
Recommendations for vitamin D supplementation are detailed in Chapter “Bone disease”.
3.4.3 Vitamin E
jj The most important physiological form of vitamin E is alpha-tocopherol.
jj Vitamin E has anti-oxidative properties which may be important for the chronic 
inflamma-tion occurring in the airways of CF patients. Its level are strongly influenced by 
serum lipid concentration. In case of low or high lipid levels, and although not widely 
recommended yet, some authors suggest to target an alpha-tocopherol:total cholesterol 
ratio >  21 mg/mmol (5.4 mg/g).
Table 9: Recommended daily dietary allowances of fat-soluble vitamins in CF3-5
Vitamin A Vitamin D Vitamin E Vitamin K 
Retinol:  4’000 – 10’000 IU 
1.2 – 3.0 mg
Beta-carotene:  1’667 IU/kg (≤ 83’300 IU) 
1 mg/kg (≤ 50 mg) for 12 weeks,  
then: 16’670 IU (10 mg)
800 – 4’000 IU
20 – 100 µg
150 – 500 IU
101 – 336 mg
5 – 10 mg
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3.4.4 Vitamin K
jj Vitamin K plays an important role in coagulation and possibly in bone homeostasis. 
jj CF-liver disease and long-term use of antibiotics may contribute to lower levels of vitamin K.
jj Vitamin K serum levels are assessed directly in the clinical laboratory. However, there is not 
clear cutoff to assess vitamin K deficiency
sj Prothrombin time is only representative of vitamin K deficiency of the liver but not of 
vitamin K status and appears insufficiently sensitive to detect mild deficiency.
sj Measurement of serum vitamin K1, PIVKA-II (proteins induced by vitamin absence) or 
under-carboxylated osteocalcin are better markers of vitamin K deficiency than pro-
thrombin time but are not available in routine clinical practice.
jj Therefore, supplementation is recommended as vitamin K is not well stored and has no 
significant toxicity.
3.4.5 Substitution of fat-soluble vitamins
jj According to the specific needs in fat-soluble vitamins, different preparations can be used. 
Available preparations are shown in Tables 10 and 11.
Table 10: Examples of vitamin A, E and K supplementation available in 
Switzerland (for vitamin D supplementation, see Chapter “Bone disease”)
Name/Type Active ingredient/Dosage
BURGERSTEIN Beta-Caroten® caps Beta carotene – vitamin A
6 mg (10’000 IU)
15 mg (25’000 IU)
BURGERSTEIN vitamin E® caps Alpha-tocopherol - vitamin E
100 UI (67 mg) 
400 UI (268 mg)
VITAMINE E Mepha® caps Alpha-tocopherol - vitamin E
300 mg (300 IU)
EVIT caps Alpha-tocopherol - vitamin E
600 UI (400 mg)
800 UI (537 mg)
EPHYNAL® caps Alpha-tocopherol - vitamin E
300 mg (300 IU)
VEDROP®
solution for oral administration
Tocophersolan - vitamin E*
expressed as tocopherol : 50 mg/mL = 75 IU/mL
DEKAs Aqua-E concentrate®
solution for oral administration
Tocophersolan - vitamin E* 
expressed as tocopherol : 50 mg/mL = 75 IU/mL
KONAKION MM®
solution for i.v. or oral administration
Phytomenadione – vitamin K 
10 mg/ml 
*Synthetic water-soluble form of vitamin E to be considered in cholestatic liver disease (delivery technology which acts 
like a micelle, facilitating absorption). Not available in Switzerland but could be imported.
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Table 11: Multivitamin and mineral supplement (for details see https://dekasvi-
tamins.com)
Name/Type Active ingredient (summary) Daily dose
DEKAs plus® softgel Vit. A + beta-carotene : 450 + 10’000 µg 
(1500 + 16'667 IU)
Vit. D3 : 75 µg (3000 IU)
Vit. E : 101 mg (150 IU)
Vit. K : 1000 µg 
Also contains hydrosoluble vitamins and 
trace elements
1-2
DEKAs plus® chewable tablet Vit. A + beta-carotene : 450 + 5014 µg 
(1500 + 16’714 IU)
Vit. D3 : 50 µg (2000 IU)
Vit. E : 67 mg (100 IU)
Vit. K : 1000 µg 
Also contains hydrosoluble vitamins and 
trace elements
1-2
DEKAs Essential® Capsule Vit. A + Beta-carotene: 150 + 900 µg 
(500 + 1500 IU)
Vit. D3 : 50 µg (2000 IU)
Vit. E : 101 mg (150 IU)
Vit. K : 1000 µg 
1-2
Supradyn Energy Vit. A (retinol palmitate): 2666 IU
Vit. D3 : 200 IU
Vit. E : 10 mg (15 IU)
Vit. K : 30 µg
Also contains hydrosoluble vitamins, 
trace elements and minerals
1
Supradyn Vital 50+ Vit. A (retinol palmitate): 1333 IU
Vit. D3 : 200 IU
Vit. E : 15 mg (22 IU)
Does not contain Vit. K
Also contains hydrosoluble vitamins, 
trace elements and minerals
1
jj AquaDEK’s®, a preparation of all fat-soluble vitamins specially intended to cover the needs 
of CF patients, is no longer available. It has been replaced by DEKA’s® (Table 11).
3.2 Oral nutritional supplements
jj There are many varieties of oral nutritional supplements regarding taste (sweet or salty), 
the amount of calories (1 or 2.4 kcal), the protein content (6 to 20 g) and the presence or 
absence of fibers. All are gluten-free (see Table S1 of the supplement).
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jj To choose the ideal oral nutritional supplement, energy needs, fiber and protein require-
ments should be considered. In general, a high-energy nutritional supplement is proposed 
as a first choice.
jj Fibers are useful especially in bowel transit disorders such as constipation or diarrhea.
jj Supplements rich in proteins are used in cases of protein loss (e.g. infection, wounds, 
important digestive losses).
3.3 Enteral nutrition
3.3.1 General considerations
jj Enteral nutrition (EN) should be considered when the patient’s overall needs are not suffi-
ciently covered by oral nutrition. It should be used in combination with oral nutrition when 
possible, or alone when oral nutrition is no longer possible. 
jj Enteral feeding is always preferred to parenteral nutrition as it is associated with less com-
plications (such as infections). Parenteral nutrition should be considered when the EN 
covers less than 60% of the needs.
jj Enteral nutrition can be provided by transnasal tubes (either nasogastric or nasojejunal), 
percutaneous endoscopic gastrostomy (PEG), percutaneous radiologic gastrostomy 
(PRG), surgical gastrostomies (GT) or percutaneous endoscopic gastrostomy with jejunal 
extension (PEG-J). 
jj Figure S1 of the supplement provides some examples of materials used for enteral 
nutrition.
3.3.2 Technical aspects
jj
jj
jj
jj
jj
jj
In CF patients requiring long-term enteral nutrition (>4 weeks), the establishment of a PEG 
or a PEG-J is preferred. Indications and contraindications are summarized in Table 12. 
Details about the care of transnasal tube, PEG and PEG-J are available in Table S2 of 
the supplement. 
Dieticians should assess the needs and the risks of undernutrition / dehydration of the 
patient and determine the daily target caloric intake (Tables 3 and 9).
High energy polymeric formulas (containing mostly intact nutrients and requiring intact 
digestive function), with or without fiber, should be preferably chosen, in addition to a mul-
tivitamin supplement with or without trace elements.
Administration of the nutrition should always be carried out via a pump to ensure a conti-
nuous flow avoiding overfeeding and bronchoaspiration. It is usually administered over-
night to allow the patient to maintain his/her autonomy and to get high-energy diet du-
ring the day. Bolus feeds can also be considered during the day in addition to 
nocturnal feeding.
Special attention should be paid to the patient’s digestive tolerance, depending on the 
type of product and its speed of administration. These aspects need to be discussed with 
the dieticians.
A raised position of the trunk at 30° is recommended during EN to avoid gastroesophageal 
reflux and bronchial aspiration.
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Table 12: Indications and contraindications for transnasal tube, PEG et PEG-J
Indications Contraindications
Transnasal
tube
Inability to meet short-term nutritio-
nal needs
Nasal polyposis
Long term (>4-6 weeks) EN
PEG
PRG
Inability to meet long-term nutritional 
needs
Neurological swallow impairment
Upper gastrointestinal tract 
neoplasm
Trauma
Patients with long-term ventilation
Perioperative period in oropharyn-
geal surgery
Severe coagulation disorders
Parietal inflammation, infectious or 
neoplasia
Cancer or gastric wall pathology
Adherence or intraperitoneal 
carcinomatosis
Gastrointestinal fistulas
PEG-J Gastric emptying disorders
Risk of aspiration pneumonia
Gastric Decompression
Pyloric stenosis 
Duodenal stenosis
EN: enteral nutrition, PEG: percutaneous endoscopic gastrostomy, PEG-J: percutaneous endoscopic gastrostomy with 
jejunal extension, PRG: percutaneous radiologic gastrostomy
jj PERT and enteral nutrition:
js Pancreatic enzyme replacement is usually given at the beginning and the end of the 
feed. At a low rate of infusion, enzyme requirements are usually low.
js Regarding dosing requirements of PERT during enteral nutrition: important variations 
exist and dose should be individualized depending on patient needs and symptoms. 
Usually the starting dose is 1’000 IU of lipase per gram of fat provided by the enteral 
nutrition but doses may range between 500-4000 IU of lipase per gram of fat or 25’000-
50’000 per meal (in case of bolus feeds).  
 – When possible, pancreatic enzymes capsules should be swallowed. For patients who 
have difficulty swallowing capsules, it is possible to open them and take their content
mixed with food or drink at a pH <5.5 (e.g. applesauce or yoghurt, apple, orange or
pineapple juice).
 – The microgranules contained in the capsule are gastro-resistant. Thus, they should
not be chewed or crushed, otherwise the efficacy of pancreatic enzymes would be
lost in the gastric acidic environment.
 – Administration of PERT through a gastrotomy feeding tube is problematic due to the
risk of tube obstruction. Dissolution of microgranules in sodium bicarbonate solution
before use is one of the proposed approaches (the solution should be prepared just
before use, the volume frequently used is 10-20 ml sodium bicarbonate solution 8.4%). 
Dosage adjustment may be necessary to compensate some loss of enzyme activity.
 – Feeding should be stopped during administration of PERT through the tube.
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jj In case of diarrhea additional adaptation may be needed (type of nutrition, flow of infusion, 
PERT). 
jj Different products are commercially available and should be discussed with the clinical 
nutrition team. A regular control of laboratory values is important after the introduction of 
enteral nutrition to prevent the refeeding syndrome.
3.4 Refeeding syndrome
jj Refeeding syndrome may occur in malnourished patients upon reintroduction of enteral 
or parenteral nutrition. It is characterized by phosphate, potassium and magnesium im-
balance but glucose, sodium and water shifts contribute also to the high morbidity and 
mortality associated with this disorder.
jj During a long duration of starvation, ketones and free fatty acids become the major source 
of energy to prevent muscle catabolism. If this state persists, catabolism and loss of lean 
body mass will occur and is associated with depletion of intracellular phosphate and va-
rious vitamins including thiamine.
jj During refeeding, carbohydrate reintroduction leads to increased levels of insulin which 
induce biochemical changes such as important intracellular shift of potassium, phosphate 
and water. In addition, glucose metabolism is altered leading to metabolic acidosis, ketoa-
cidosis and hyperosmolar states. 
jj Patients will therefore suffer from cardiac, respiratory, renal, neurological, gastrointestinal, 
musculoskeletal and hematological consequences of hypophosphatemia, hypokalemia, 
hypomagnesemia, hypocalcemia and hypovitaminosis (such as B1 hypovitaminosis).
jj It is therefore crucial to identify patients at risk for refeeding syndrome. Nice criteria have 
been established to detect such patients (Table 13). Nutrition reintroduction in patients 
at risk for refeeding syndrome must be performed in close collaboration with the nutrition 
team. Biological and clinical monitoring is required during this delicate phase.
Table 13: Nice criteria2: patients at high risk for refeeding syndrome
Patient has one or more of the following:
BMI less than 16 kg/m2
Unintentional weight loss greater than 15% within the last 3–6 months
Little or no nutritional intake for more than 10 days
Low levels of potassium, phosphate or magnesium prior to feeding
Or patient has two or more of the following:
BMI less than 18.5 kg/m2
Unintentional weight loss greater than 10% within the last 3–6 months
Little or no nutritional intake for more than 5 days
History of alcohol abuse or drugs including insulin, chemotherapy, antacids or diuretics
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4. SPECIAL SITUATIONS
4.1 Pregnancy
jj
jj
jj
jj
jj
jj
jj
Counseling before conception should be offered to all CF women.
Reassess fat-soluble vitamin levels to avoid excessive dosages (notably of vitamin A). 
Supplementation of folic acid (0.4mg/day) is recommended for all pregnant women. 
Increasing the frequency of monitoring is recommended during pregnancy, with a close 
follow-up after delivery. 
Nutritional needs rise during breastfeeding. Therefore, nutritional status should be reas-
sessed following delivery in CF women at risk for undernutrition. Breastfeeding may have 
to be interrupted in this case.
If the lactating woman is diabetic, she is at risk for hypoglycemia.
Information about gestational diabetes screening is provided in Chapter “CF-related 
diabetes”.
4.2 CF-related diabetes (see also Chapter “CF-related diabetes”)
jj CF patients newly diagnosed with CF-related diabetes should continue to get high ener-
gy diets and should not be encouraged to reduce their consumption of carbohydrates. 
Instead, close glucose level monitoring is advised in order to adjust insulin needs. 
5. SUMMARY
jj Figure 3 provides an algorithm for nutritional intervention in CF
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Figure 3: Algorithm for nutritional intervention in CF (adapted from 4,5,7)
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Table S1: Examples of oral nutritional supplements available in Switzerland
Name Company Quantity 
(ml)
Kcal Protein 
(g)
Caracteristics Flavor
Ensure Plus Abott SA 200 300 12.5 High energy, 
fiber-free, normal 
protein, gluten-
free, virtually 
lactose-free
Fruits of the 
forest, Strawberry, 
Raspberry, 
Coffee, Chocolate, 
Banana, Vanilla
Ensure Plus 
Advance
Abott SA 220 330 20 High energy, en-
riched fiber, high 
protein, gluten-
free, low lactose
Peach, 
Pinacolada
Ensure 
TwoCal
Abott SA 200 400 16.8 High energy, 
fiber-free, normal 
protein, gluten-
free, virtually 
lactose-free
Vanilla, Banana, 
Strawberry
Fresubin 
Energy 
Drink
Fresenius 
Kabi
200 300 11.2 High energy, 
fiber-free, normal 
protein, gluten-
free, virtually 
lactose-free
Cappuccino, 
Cassis, Vanilla, 
Strawberry, Exotic 
fruits
Fresubin 2 
kcal Drink
Fresenius 
Kabi
200 400 20 High energy, 
enriched fiber, 
high protein, 
gluten-free, low 
lactose
Fruits of the 
forest, Vanilla, 
Nature, 
Apricot-peach
Fresubin 
Protein 
Energy 
Drink
Fresenius 
Kabi
200 300 20 High  energy, 
high protein, 
gluten-free, 
virtually 
lactose-free
Chocolate, 
Vanilla, Wild 
strawberry, 
Hazelnut, 
Cappucino, 
Tropical fruits
Resource 
Energy
Nestlé 200 300 11.2 High energy, 
fiber-free, normal 
protein, gluten-
free, low lactose
Vanilla, Apricot, 
Chocolate, 
Strawberry-
raspberry, Coffee, 
Banana
S6.7 Nutrition
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Resource 
2.0 Fibres
Nestlé 200 400 18 High energy, 
enriched fiber, 
high protein, 
gluten-free, low 
lactose
Vanilla, 
Apricot, Fruits 
of the forest, 
Nature, Coffee, 
Strawberry, 
Chocolate
Resource 
Protein
Neslté 200 250 18.6 High energy, 
high protein, 
gluten-free, 
virtually lactose-
free
Vanilla, Apricot, 
Fruits of the 
 forest, Strawberry
Fortimel 
Energy
Nutricia 200 300 12 High energy, 
normal protein, 
gluten-free, 
lactose-free
Strawberry, 
Banana, 
Chocolate, Vanilla
Fortimel 
Protein
Nutricia 200 480 29 High energy, 
high protein, 
gluten-free, low 
lactose
Vanilla, Moka, 
Banana, 
Strawberry, Red 
Fruits, Peach-
mango, Mutlifruits
Fortimel 
Energy Multi 
Fibre
Nutricia 200 308 12 High  energy, 
enriched 
fiber, normal 
protein, gluten-
free, virtually 
lactose-free
Vanilla, 
Chocolate, 
Strawberry
Proposed approach when using enteral feeding
jj Wash hands before and after handling.
jj Administer only still water (no acidic beverages).
jj Unblock the probe, if necessary, with carbonated water (preferably) or coca beverage 
(may color the probe) using a 10 ml syringe. 
jj Check the position of the probe by removing some gastric fluid.
jj Rinse before and after feeding.
jj Rinse before, between each medication and after each medication.
jj Monitor patient’s fluid balance, perform input-output assessments if necessary.
jj Replace tubing every 24 hours.
jj Clean the tip of the probe with hot water and possibly with a new toothbrush.
jj Stoma care daily.
jj If the ostomy is not used, rinse it once a day with 20 ml of water.
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jj Track whether the target caloric coverage is reached (weight, consultation by dietician).
jj Pain should be carefully evaluated but usually resolves within a few days. Mild analgesics 
are sufficient most of the time. 
jj Diarrhea can occur if the nutrition is too cool or open for >24h before usage. If diarrhea 
continues discussion with the dieticians is required to adapt the nutrition (type of nutrition, 
flow of infusion, PERT). 
jj Insertion point: should be regularly checked for redness, chemical burns on effluent regur-
gitation/nutrition, granulation, eschar. 
jj If necessary, disinfection with a non-alcoholic and non-colored antiseptic. 
jj In case of fever medical advice should be sought.
jj Ensure that the patient has access to a psychological support as body image change may 
have a psychological impact.
Table S2: Enteral nutrition devices and their specific care
Feeding tube Tubes and set up Specific care Precautions/
complications
Transnasal tube • Small diameter
probes (Freka®,
Bengmark®),
more likely to get
clogged.
• In general, these
probes are
positioned to the
gastric level, if
necessary, they
can be moved to
the jejunal level.
• Post-
implementation
X-ray to ensure
proper placement.
• This probe is at-
tached to the nose
and the cheek.
• Always prefer me-
dications in liquid
form.  Administer
one drug at a
time and rinse
well with 20 cc of
tap water. Always
rinse between 2
drugs to avoid
precipitation.
• A pen mark will
identify the exit of
the probe at the
nose and will allow
to verify that it
remains in place.
• In CF patients,
recurrent cough can
cause migration
of the tube in the
airways.
• Change the
 location of the
fixation of the
extremity of the
probe every day to
reduce the risk of
pressure ulcers and
of nasal bleeding.
• It may be
 associated with nau-
sea, vomiting, gas-
tro-esophageal reflux,
sleep disturbance.
• If the EN is
planned for a long-
term, a percu-
taneous gastrostomy
should be conside-
red early.
(continued)
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PEG 
(Percutanuous 
Endoscopic 
Gastrostomy) 
• The feeding tube
is inserted through
the abdominal
wall and into
the  stomach. It
is placed under
endoscopic
guidance, usually
under general
anesthesia.
• A collar allows to
attach the probe
to the gastric wall,
while a fin or a
washer allows
to maintain the
 device on the skin.
• At the end of the
procedure, the
probe is put under
tension and under
a bandage.
• The operator
should take care
of the first change
of the bandage
and the first
mobilization of the
tube (starting on
day 6) to allow the
adhesion of the di-
gestive wall to the
skin and to avoid
the risk of peri-
toneal passage of
the EN.
• From day 6 to day
16, sterile ban-
dage and probe
mobilizations
should be done
daily.
• From day 16, as
a general rule, the
probe is kept in
the air and mobi-
lizations continue
at the same pace.
This mobilization
should be done,
after having
released the probe
of the device
which keeps it in
tension with the
skin.
• For PEG with fin,
repair kits allow
the replacement
of all or part of the
broken externa-
lized device.
• Unless there is a
contraindication, the
tube can be safely
used 3 to 6 hours
after insertion. Sterile
saline should be in-
fused first to evaluate
the permeability of
the system (intra
peritoneal infiltration
would cause severe
pain).
Mobilization:
• Back and forth at
least 1 to 2 cm to
avoid impaction
of the collar in the
gastric mucosa (this
may lead to loss
of permeability of
the PEG and partial
gastrectomy).
• Rotation of the probe
from 90 to 180° to
avoid pressure sores.
It is recommended to
make these rotations
always in the same
direction (defined
at the beginning) to
keep as much as
possible the same
diameter and the
symmetry of the
ostomy (limiting
the risks of regur-
gitation of gastric
juice and diet on the
cutaneous plane
and associated
dermatitis).
(continued)
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• Once mobilization is
complete, the probe
will be re-tensioned
gently when it is
reattached to the fin
or the washer.
• When the device
contains a washer,
the strength of the
fixation may de-
crease over time: the
tension should be
checked regularly.
• PEG may be left in
place for 4 weeks to
several years, but
in the long-term the
transition to a gastric
tube (the collar that
fixes the probe to
the gastric wall is
replaced by a bal-
loon filled with water)
or a gastrostomy
button should be
considered as they
are more convenient
for the patient. In
these cases, the
PEG is first removed
endoscopically.
• Patients may com-
plain of post-insertion
pain
• Leakage and infec-
tion at the site of
gastrostomy may oc-
cur and need topical
treatment (antibiotic,
steroid)
(continued)
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PRG 
(Percutaneous 
Radiologic 
Gastrostomy)
• The feeding tube
is directly inserted
through the abdo-
minal wall into the
stomach under CT
scan or ultrasound
guidance (to
avoid penetration
through the colon
if interposed).
• Previous pigtail
tubes have been
increasingly re-
placed by gastric
tubes.
 If a gastric tube 
has been placed:
• The operator
should take care
of the first change
of sterile bandage
starting day 6.
• From day 6 to day
15, daily cleaning
with 0.9% NaCl
and disinfection
with aqueous di-
sinfectant without
dye followed by
sterile bandage.
• At day 15, as a
general rule, the
probe should be
kept in the air
and mobilization
should continue
at the same pace.
This mobilization
will be done, after
having released
the probe of the
device which
keeps it in tension
with the skin.
• Sutures are
removed on day
15 (or according
to medical order)
and then daily mo-
bilization should
begin.
• Unless there is a
contraindication, the
tube can be safely
used 3 to 6 hours after
insertion. Sterile saline
should be infused
first to evaluate the
permeability of the
system (intra peri-
toneal infiltration would
cause severe pain).
• The balloon of the
gastric tube needs to
be checked regularly
to ensure it remains
well sealed (the
quantity of water to
introduce may vary
according to the
gastrostomy model
but is kept the same
until the change of
the device).
• An advantage of the
gastric tube is that
it can be changed
by the patient or a
caregiver.
• In case of loss or
untimely tearing
of the device, a
new gastric tube
must be reinserted
within 6 hours
(otherwise the
ostomy may close
spontaneously).
The patient should
be strongly advised
to carry on him a
spare device.
• Patients may com-
plain of post-insertion
pain.
(continued)
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• Leakage and infec-
tion at the site of
gastrostomy may oc-
cur needing topical
treatment (antibiotic,
steroid).
PEG –J or PEJ
(percutaneous en-
doscopic gastros-
tomy with jejunal 
extension)
• If needed a PEG
can be extended
to the jejunal level.
• Tube rotations
are proscribed
because of the
risk of probe
dislocation.
• Mobilization of
the tube (small
movements back
and forth) should
be performed
daily from day 6
with much caution
to avoid dislod-
gement from the
jejunum.
• A gastric tube or a
gastrostomy button
cannot be extended
to the jejunum
• As with all jejunal
feeding routes, never
aspirate (no gastric
residue).
Surgical 
jejunostomy
• The tube is surgi-
cally inserted into
the jejunum after
the ligament of
Treitz.
• No mobilization of
the device should
be performed.
• As with all jejunal
feeding routes, never
aspirate (no gastric
residue).
S6.7 Nutrition.indd   7 08/05/19   12:35 PM
